Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 32 entries
Sorted by: Best Match Show Resources per page
Regioselective functionalization of alkanes by sequential dehydrogenation-hydrozirconation.

Chemical communications (Cambridge, England)

Kuninobu Y, Ureshino T, Yamamoto S, Takai K.
PMID: 20548990
Chem Commun (Camb). 2010 Aug 07;46(29):5310-2. doi: 10.1039/c0cc00243g. Epub 2010 Jun 14.

We have succeeded in formal regioselective functionalization of alkanes by iridium-catalyzed dehydrogenation, hydrozirconation of the resulting alkenes, and electrophilic reaction of the generated alkylzirconium intermediate.

Cite
Kuninobu Y, Ureshino T, Yamamoto S, et al. Regioselective functionalization of alkanes by sequential dehydrogenation-hydrozirconation. Chem Commun (Camb). 2010;46(29):5310-2doi: 10.1039/c0cc00243g.
Kuninobu, Y., Ureshino, T., Yamamoto, S., & Takai, K. (2010). Regioselective functionalization of alkanes by sequential dehydrogenation-hydrozirconation. Chemical communications (Cambridge, England), 46(29), 5310-2. https://doi.org/10.1039/c0cc00243g
Kuninobu, Yoichiro, et al. "Regioselective functionalization of alkanes by sequential dehydrogenation-hydrozirconation." Chemical communications (Cambridge, England) vol. 46,29 (2010): 5310-2. doi: https://doi.org/10.1039/c0cc00243g
Kuninobu Y, Ureshino T, Yamamoto S, Takai K. Regioselective functionalization of alkanes by sequential dehydrogenation-hydrozirconation. Chem Commun (Camb). 2010 Aug 07;46(29):5310-2. doi: 10.1039/c0cc00243g. Epub 2010 Jun 14. PMID: 20548990.
Copy Download .nbib Format: NLM
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).

BMC cancer

Shibuki T, Mizuta T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Mitsugi K, Nio K, Ide Y, Ureshino N, Shirakawa T, Otsuka T.
PMID: 34980029
BMC Cancer. 2022 Jan 03;22(1):19. doi: 10.1186/s12885-021-09139-y.

BACKGROUND: No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab-paclitaxel (GnP) or FOLFIRINOX.METHODS: This analysis was conducted using clinical data of Japanese patients with...

Cite
Shibuki T, Mizuta T, Shimokawa M, et al. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC Cancer. 2022;22(1):19doi: 10.1186/s12885-021-09139-y.
Shibuki, T., Mizuta, T., Shimokawa, M., Koga, F., Ueda, Y., Nakazawa, J., Komori, A., Otsu, S., Arima, S., Fukahori, M., Makiyama, A., Taguchi, H., Honda, T., Mitsugi, K., Nio, K., Ide, Y., Ureshino, N., Shirakawa, T., & Otsuka, T. (2022). Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC cancer, 22(1), 19. https://doi.org/10.1186/s12885-021-09139-y
Shibuki, Taro, et al. "Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)." BMC cancer vol. 22,1 (2022): 19. doi: https://doi.org/10.1186/s12885-021-09139-y
Shibuki T, Mizuta T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Mitsugi K, Nio K, Ide Y, Ureshino N, Shirakawa T, Otsuka T. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC Cancer. 2022 Jan 03;22(1):19. doi: 10.1186/s12885-021-09139-y. PMID: 34980029; PMCID: PMC8722136.
Copy Download .nbib Format: NLM
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).

Journal of geriatric oncology

Koga F, Kawaguchi Y, Shimokawa M, Murayama K, Nakashita S, Oza N, Ureshino N, Takahashi H, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Shirakawa T, Otsuka T, Mitsugi K.
PMID: 34215525
J Geriatr Oncol. 2022 Jan;13(1):82-87. doi: 10.1016/j.jgo.2021.06.011. Epub 2021 Jun 29.

OBJECTIVES: This study aimed to examine the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) in older patients with metastatic pancreatic cancer (MPC), especially those ≥75 years old.MATERIALS AND METHODS: This study retrospectively enrolled 153 patients with MPC who...

Cite
Koga F, Kawaguchi Y, Shimokawa M, et al. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study). J Geriatr Oncol. 2021;13(1):82-87doi: 10.1016/j.jgo.2021.06.011.
Koga, F., Kawaguchi, Y., Shimokawa, M., Murayama, K., Nakashita, S., Oza, N., Ureshino, N., Takahashi, H., Ueda, Y., Nakazawa, J., Komori, A., Otsu, S., Arima, S., Fukahori, M., Makiyama, A., Taguchi, H., Honda, T., Shibuki, T., Nio, K., Ide, Y., Mizuta, T., Shirakawa, T., Otsuka, T., & Mitsugi, K. (2022). Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study). Journal of geriatric oncology, 13(1), 82-87. https://doi.org/10.1016/j.jgo.2021.06.011
Koga, Futa, et al. "Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)." Journal of geriatric oncology vol. 13,1 (2022): 82-87. doi: https://doi.org/10.1016/j.jgo.2021.06.011
Koga F, Kawaguchi Y, Shimokawa M, Murayama K, Nakashita S, Oza N, Ureshino N, Takahashi H, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Shirakawa T, Otsuka T, Mitsugi K. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study). J Geriatr Oncol. 2022 Jan;13(1):82-87. doi: 10.1016/j.jgo.2021.06.011. Epub 2021 Jun 29. PMID: 34215525.
Copy Download .nbib Format: NLM
A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression.

Case reports in oncology

Wada Y, Takami Y, Ryu T, Ureshino H, Imamura H, Sasaki S, Saitsu H.
PMID: 32355493
Case Rep Oncol. 2020 Apr 09;13(1):379-384. doi: 10.1159/000506331. eCollection 2020.

A 73-year-old male was initially treated with sorafenib for advanced stage HCC. However, the disease progressed 2 months after starting sorafenib. Progressive disease (PD) was confirmed by radiological examination, which revealed mediastinal and abdominal lymph node metastasis, pulmonary metastasis,...

Cite
Wada Y, Takami Y, Ryu T, et al. A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression. Case Rep Oncol. 2020;13(1):379-384doi: 10.1159/000506331.
Wada, Y., Takami, Y., Ryu, T., Ureshino, H., Imamura, H., Sasaki, S., & Saitsu, H. (2020). A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression. Case reports in oncology, 13(1), 379-384. https://doi.org/10.1159/000506331
Wada, Yoshiyuki, et al. "A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression." Case reports in oncology vol. 13,1 (2020): 379-384. doi: https://doi.org/10.1159/000506331
Wada Y, Takami Y, Ryu T, Ureshino H, Imamura H, Sasaki S, Saitsu H. A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression. Case Rep Oncol. 2020 Apr 09;13(1):379-384. doi: 10.1159/000506331. eCollection 2020. PMID: 32355493; PMCID: PMC7184828.
Copy Download .nbib Format: NLM
Allelic polymorphisms of .

Immunological medicine

Shindo T, Ureshino H, Kojima H, Tanaka H, Kimura S.
PMID: 32715973
Immunol Med. 2021 Jun;44(2):61-68. doi: 10.1080/25785826.2020.1796062. Epub 2020 Jul 25.

The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) markedly improved the prognosis of patients with chronic myeloid leukemia (CML). Approximately 50% of patients who achieve deep molecular response (DMR) remain in treatment-free remission (TFR) even after discontinuation of TKIs....

Cite
Shindo T, Ureshino H, Kojima H, et al. Allelic polymorphisms of . Immunol Med. 2020;44(2):61-68doi: 10.1080/25785826.2020.1796062.
Shindo, T., Ureshino, H., Kojima, H., Tanaka, H., & Kimura, S. (2021). Allelic polymorphisms of . Immunological medicine, 44(2), 61-68. https://doi.org/10.1080/25785826.2020.1796062
Shindo, Takero, et al. "Allelic polymorphisms of ." Immunological medicine vol. 44,2 (2021): 61-68. doi: https://doi.org/10.1080/25785826.2020.1796062
Shindo T, Ureshino H, Kojima H, Tanaka H, Kimura S. Allelic polymorphisms of . Immunol Med. 2021 Jun;44(2):61-68. doi: 10.1080/25785826.2020.1796062. Epub 2020 Jul 25. PMID: 32715973.
Copy Download .nbib Format: NLM
Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.

Cancer letters

Kamachi K, Ureshino H, Watanabe T, Yoshida N, Yamamoto Y, Kurahashi Y, Fukuda-Kurahashi Y, Hayashi Y, Hirai H, Yamashita S, Ushijima T, Okada S, Kimura S.
PMID: 34875342
Cancer Lett. 2022 Feb 01;526:273-283. doi: 10.1016/j.canlet.2021.11.032. Epub 2021 Dec 04.

ABL1 tyrosine kinase inhibitors (TKIs) dramatically improve the prognosis of chronic myeloid leukemia (CML), but 10-20% of patients achieve suboptimal responses with low TKIs sensitivity. Furthermore, residual leukemic stem cells (LSCs) are involved in the molecular relapse after TKIs...

Cite
Kamachi K, Ureshino H, Watanabe T, et al. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer Lett. 2021;526:273-283doi: 10.1016/j.canlet.2021.11.032.
Kamachi, K., Ureshino, H., Watanabe, T., Yoshida, N., Yamamoto, Y., Kurahashi, Y., Fukuda-Kurahashi, Y., Hayashi, Y., Hirai, H., Yamashita, S., Ushijima, T., Okada, S., & Kimura, S. (2022). Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer letters, 526273-283. https://doi.org/10.1016/j.canlet.2021.11.032
Kamachi, Kazuharu, et al. "Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia." Cancer letters vol. 526 (2022): 273-283. doi: https://doi.org/10.1016/j.canlet.2021.11.032
Kamachi K, Ureshino H, Watanabe T, Yoshida N, Yamamoto Y, Kurahashi Y, Fukuda-Kurahashi Y, Hayashi Y, Hirai H, Yamashita S, Ushijima T, Okada S, Kimura S. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer Lett. 2022 Feb 01;526:273-283. doi: 10.1016/j.canlet.2021.11.032. Epub 2021 Dec 04. PMID: 34875342.
Copy Download .nbib Format: NLM
Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.

Molecular cancer therapeutics

Ureshino H, Kurahashi Y, Watanabe T, Yamashita S, Kamachi K, Yamamoto Y, Fukuda-Kurahashi Y, Yoshida-Sakai N, Hattori N, Hayashi Y, Kawaguchi A, Tohyama K, Okada S, Harada H, Ushijima T, Kimura S.
PMID: 34045225
Mol Cancer Ther. 2021 Aug;20(8):1412-1421. doi: 10.1158/1535-7163.MCT-20-1125. Epub 2021 May 27.

DNA methyltransferase inhibitors have improved the prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, because these agents are easily degraded by cytidine deaminase (CDA), they must be administered intravenously or subcutaneously. Recently, two orally bioavailable DNA...

Cite
Ureshino H, Kurahashi Y, Watanabe T, et al. Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. Mol Cancer Ther. 2021;20(8):1412-1421doi: 10.1158/1535-7163.MCT-20-1125.
Ureshino, H., Kurahashi, Y., Watanabe, T., Yamashita, S., Kamachi, K., Yamamoto, Y., Fukuda-Kurahashi, Y., Yoshida-Sakai, N., Hattori, N., Hayashi, Y., Kawaguchi, A., Tohyama, K., Okada, S., Harada, H., Ushijima, T., & Kimura, S. (2021). Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. Molecular cancer therapeutics, 20(8), 1412-1421. https://doi.org/10.1158/1535-7163.MCT-20-1125
Ureshino, Hiroshi, et al. "Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects." Molecular cancer therapeutics vol. 20,8 (2021): 1412-1421. doi: https://doi.org/10.1158/1535-7163.MCT-20-1125
Ureshino H, Kurahashi Y, Watanabe T, Yamashita S, Kamachi K, Yamamoto Y, Fukuda-Kurahashi Y, Yoshida-Sakai N, Hattori N, Hayashi Y, Kawaguchi A, Tohyama K, Okada S, Harada H, Ushijima T, Kimura S. Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. Mol Cancer Ther. 2021 Aug;20(8):1412-1421. doi: 10.1158/1535-7163.MCT-20-1125. Epub 2021 May 27. PMID: 34045225.
Copy Download .nbib Format: NLM
Overexpression of α-synuclein inhibits mitochondrial Ca.

Journal of neuroscience research

Erustes AG, D'Eletto M, Guarache GC, Ureshino RP, Bincoletto C, da Silva Pereira GJ, Piacentini M, Smaili SS.
PMID: 34510532
J Neurosci Res. 2021 Nov;99(11):2932-2947. doi: 10.1002/jnr.24952. Epub 2021 Sep 12.

Mitochondria-associated ER membranes (MAMs) are formed by close and specific components in the contact sites between the endoplasmic reticulum (ER) and mitochondria, which participate in several cell functions, including lipid metabolism, autophagy, and Ca

Cite
Erustes AG, D'Eletto M, Guarache GC, et al. Overexpression of α-synuclein inhibits mitochondrial Ca. J Neurosci Res. 2021;99(11):2932-2947doi: 10.1002/jnr.24952.
Erustes, A. G., D'Eletto, M., Guarache, G. C., Ureshino, R. P., Bincoletto, C., da Silva Pereira, G. J., Piacentini, M., & Smaili, S. S. (2021). Overexpression of α-synuclein inhibits mitochondrial Ca. Journal of neuroscience research, 99(11), 2932-2947. https://doi.org/10.1002/jnr.24952
Erustes, Adolfo Garcia, et al. "Overexpression of α-synuclein inhibits mitochondrial Ca." Journal of neuroscience research vol. 99,11 (2021): 2932-2947. doi: https://doi.org/10.1002/jnr.24952
Erustes AG, D'Eletto M, Guarache GC, Ureshino RP, Bincoletto C, da Silva Pereira GJ, Piacentini M, Smaili SS. Overexpression of α-synuclein inhibits mitochondrial Ca. J Neurosci Res. 2021 Nov;99(11):2932-2947. doi: 10.1002/jnr.24952. Epub 2021 Sep 12. PMID: 34510532.
Copy Download .nbib Format: NLM
Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.

Cancer letters

Kamachi K, Ureshino H, Watanabe T, Yoshida N, Yamamoto Y, Kurahashi Y, Fukuda-Kurahashi Y, Hayashi Y, Hirai H, Yamashita S, Ushijima T, Okada S, Kimura S.
PMID: 34875342
Cancer Lett. 2021 Dec 04;526:273-283. doi: 10.1016/j.canlet.2021.11.032. Epub 2021 Dec 04.

ABL1 tyrosine kinase inhibitors (TKIs) dramatically improve the prognosis of chronic myeloid leukemia (CML), but 10-20% of patients achieve suboptimal responses with low TKIs sensitivity. Furthermore, residual leukemic stem cells (LSCs) are involved in the molecular relapse after TKIs...

Cite
Kamachi K, Ureshino H, Watanabe T, et al. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer Lett. 2021;526:273-283doi: 10.1016/j.canlet.2021.11.032.
Kamachi, K., Ureshino, H., Watanabe, T., Yoshida, N., Yamamoto, Y., Kurahashi, Y., Fukuda-Kurahashi, Y., Hayashi, Y., Hirai, H., Yamashita, S., Ushijima, T., Okada, S., & Kimura, S. (2021). Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer letters, 526273-283. https://doi.org/10.1016/j.canlet.2021.11.032
Kamachi, Kazuharu, et al. "Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia." Cancer letters vol. 526 (2021): 273-283. doi: https://doi.org/10.1016/j.canlet.2021.11.032
Kamachi K, Ureshino H, Watanabe T, Yoshida N, Yamamoto Y, Kurahashi Y, Fukuda-Kurahashi Y, Hayashi Y, Hirai H, Yamashita S, Ushijima T, Okada S, Kimura S. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer Lett. 2021 Dec 04;526:273-283. doi: 10.1016/j.canlet.2021.11.032. Epub 2021 Dec 04. PMID: 34875342.
Copy Download .nbib Format: NLM
Overexpression of α-synuclein inhibits mitochondrial Ca.

Journal of neuroscience research

Erustes AG, D'Eletto M, Guarache GC, Ureshino RP, Bincoletto C, da Silva Pereira GJ, Piacentini M, Smaili SS.
PMID: 34510532
J Neurosci Res. 2021 Nov;99(11):2932-2947. doi: 10.1002/jnr.24952. Epub 2021 Sep 12.

Mitochondria-associated ER membranes (MAMs) are formed by close and specific components in the contact sites between the endoplasmic reticulum (ER) and mitochondria, which participate in several cell functions, including lipid metabolism, autophagy, and Ca

Cite
Erustes AG, D'Eletto M, Guarache GC, et al. Overexpression of α-synuclein inhibits mitochondrial Ca. J Neurosci Res. 2021;99(11):2932-2947doi: 10.1002/jnr.24952.
Erustes, A. G., D'Eletto, M., Guarache, G. C., Ureshino, R. P., Bincoletto, C., da Silva Pereira, G. J., Piacentini, M., & Smaili, S. S. (2021). Overexpression of α-synuclein inhibits mitochondrial Ca. Journal of neuroscience research, 99(11), 2932-2947. https://doi.org/10.1002/jnr.24952
Erustes, Adolfo Garcia, et al. "Overexpression of α-synuclein inhibits mitochondrial Ca." Journal of neuroscience research vol. 99,11 (2021): 2932-2947. doi: https://doi.org/10.1002/jnr.24952
Erustes AG, D'Eletto M, Guarache GC, Ureshino RP, Bincoletto C, da Silva Pereira GJ, Piacentini M, Smaili SS. Overexpression of α-synuclein inhibits mitochondrial Ca. J Neurosci Res. 2021 Nov;99(11):2932-2947. doi: 10.1002/jnr.24952. Epub 2021 Sep 12. PMID: 34510532.
Copy Download .nbib Format: NLM
Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.

Cancer letters

Kamachi K, Ureshino H, Watanabe T, Yoshida N, Yamamoto Y, Kurahashi Y, Fukuda-Kurahashi Y, Hayashi Y, Hirai H, Yamashita S, Ushijima T, Okada S, Kimura S.
PMID: 34875342
Cancer Lett. 2021 Dec 04;526:273-283. doi: 10.1016/j.canlet.2021.11.032. Epub 2021 Dec 04.

ABL1 tyrosine kinase inhibitors (TKIs) dramatically improve the prognosis of chronic myeloid leukemia (CML), but 10-20% of patients achieve suboptimal responses with low TKIs sensitivity. Furthermore, residual leukemic stem cells (LSCs) are involved in the molecular relapse after TKIs...

Cite
Kamachi K, Ureshino H, Watanabe T, et al. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer Lett. 2021;526:273-283doi: 10.1016/j.canlet.2021.11.032.
Kamachi, K., Ureshino, H., Watanabe, T., Yoshida, N., Yamamoto, Y., Kurahashi, Y., Fukuda-Kurahashi, Y., Hayashi, Y., Hirai, H., Yamashita, S., Ushijima, T., Okada, S., & Kimura, S. (2021). Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer letters, 526273-283. https://doi.org/10.1016/j.canlet.2021.11.032
Kamachi, Kazuharu, et al. "Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia." Cancer letters vol. 526 (2021): 273-283. doi: https://doi.org/10.1016/j.canlet.2021.11.032
Kamachi K, Ureshino H, Watanabe T, Yoshida N, Yamamoto Y, Kurahashi Y, Fukuda-Kurahashi Y, Hayashi Y, Hirai H, Yamashita S, Ushijima T, Okada S, Kimura S. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer Lett. 2021 Dec 04;526:273-283. doi: 10.1016/j.canlet.2021.11.032. Epub 2021 Dec 04. PMID: 34875342.
Copy Download .nbib Format: NLM
Cannabidiol induces autophagy via ERK1/2 activation in neural cells.

Scientific reports

Vrechi TAM, Leão AHFF, Morais IBM, Abílio VC, Zuardi AW, Hallak JEC, Crippa JA, Bincoletto C, Ureshino RP, Smaili SS, Pereira GJS.
PMID: 33686185
Sci Rep. 2021 Mar 08;11(1):5434. doi: 10.1038/s41598-021-84879-2.

Autophagy is a lysosomal catabolic process essential to cell homeostasis and is related to the neuroprotection of the central nervous system. Cannabidiol (CBD) is a non-psychotropic phytocannabinoid present in Cannabis sativa. Many therapeutic actions have been linked to this...

Cite
Vrechi TAM, Leão AHFF, Morais IBM, et al. Cannabidiol induces autophagy via ERK1/2 activation in neural cells. Sci Rep. 2021;11(1):5434doi: 10.1038/s41598-021-84879-2.
Vrechi, T. A. M., Leão, A. H. F. F., Morais, I. B. M., Abílio, V. C., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A., Bincoletto, C., Ureshino, R. P., Smaili, S. S., & Pereira, G. J. S. (2021). Cannabidiol induces autophagy via ERK1/2 activation in neural cells. Scientific reports, 11(1), 5434. https://doi.org/10.1038/s41598-021-84879-2
Vrechi, Talita A M, et al. "Cannabidiol induces autophagy via ERK1/2 activation in neural cells." Scientific reports vol. 11,1 (2021): 5434. doi: https://doi.org/10.1038/s41598-021-84879-2
Vrechi TAM, Leão AHFF, Morais IBM, Abílio VC, Zuardi AW, Hallak JEC, Crippa JA, Bincoletto C, Ureshino RP, Smaili SS, Pereira GJS. Cannabidiol induces autophagy via ERK1/2 activation in neural cells. Sci Rep. 2021 Mar 08;11(1):5434. doi: 10.1038/s41598-021-84879-2. PMID: 33686185; PMCID: PMC7940388.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 32 entries